This project is part of a Blood and Marrow Transplant Clinical Research Network which is conducting multicenter clinical trials in hematopoietic stem cell transplantation. The purpose of the network is to promote the efficient comparison of novel treatment methods and management strategies of potential benefit for children and adults undergoing blood or marrow transplantation. Studies under development include a comparison of blood versus marrow stem cell transplantation. Studies under development include a comparison of blood versus marrow stem cell transplantation after marrow ablation, the development of non-myeloablative transplant regimens, and the best ways to avoid infections in transplant patients.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01HL069286-04
Application #
6801839
Study Section
Special Emphasis Panel (ZHL1-CSR-F (S1))
Program Officer
Henslee-Downey, Jean
Project Start
2001-09-30
Project End
2006-08-31
Budget Start
2004-09-27
Budget End
2005-08-31
Support Year
4
Fiscal Year
2004
Total Cost
$405,000
Indirect Cost
Name
University of Pennsylvania
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Reshef, Ran; Ganetsky, Alex; Acosta, Edward P et al. (2018) Extended CCR5 Blockade for Graft-versus-Host Disease Prophylaxis Improves Outcomes of Reduced-Intensity Unrelated Donor Hematopoietic Cell Transplantation: A Phase II Clinical Trial. Biol Blood Marrow Transplant :
Crisalli, Lisa M; Hinkle, Joanne T; Walling, Christopher C et al. (2018) Higher Donor Apheresis Blood Volumes Are Associated with Reduced Relapse Risk and Improved Survival in Reduced-Intensity Allogeneic Transplantations with Unrelated Donors. Biol Blood Marrow Transplant 24:1203-1208
Huffman, Austin P; Richman, Lee P; Crisalli, Lisa et al. (2018) Pharmacodynamic Monitoring Predicts Outcomes of CCR5 Blockade as Graft-versus-Host Disease Prophylaxis. Biol Blood Marrow Transplant 24:594-599
Moy, Ryan H; Huffman, Austin P; Richman, Lee P et al. (2017) Clinical and immunologic impact of CCR5 blockade in graft-versus-host disease prophylaxis. Blood 129:906-916
Ganetsky, A; Shah, A; Miano, T A et al. (2016) Higher tacrolimus concentrations early after transplant reduce the risk of acute GvHD in reduced-intensity allogeneic stem cell transplantation. Bone Marrow Transplant 51:568-72
Reshef, Ran; Huffman, Austin P; Gao, Amy et al. (2015) High Graft CD8 Cell Dose Predicts Improved Survival and Enables Better Donor Selection in Allogeneic Stem-Cell Transplantation With Reduced-Intensity Conditioning. J Clin Oncol 33:2392-8
Reshef, Ran; Hexner, Elizabeth O; Loren, Alison W et al. (2014) Early donor chimerism levels predict relapse and survival after allogeneic stem cell transplantation with reduced-intensity conditioning. Biol Blood Marrow Transplant 20:1758-66
Reshef, Ran; Luger, Selina M; Hexner, Elizabeth O et al. (2012) Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease. N Engl J Med 367:135-45
Reshef, R; Luskin, M R; Kamoun, M et al. (2011) Association of HLA polymorphisms with post-transplant lymphoproliferative disorder in solid-organ transplant recipients. Am J Transplant 11:817-25
Reshef, R; Vardhanabhuti, S; Luskin, M R et al. (2011) Reduction of immunosuppression as initial therapy for posttransplantation lymphoproliferative disorder(?). Am J Transplant 11:336-47